Aquestive Therapeutics, Inc.
AQST
$2.87
$0.020.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 11.87M | 13.54M | 20.10M | 12.05M | 13.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.87M | 13.54M | 20.10M | 12.05M | 13.21M |
| Cost of Revenue | 4.52M | 4.44M | 4.53M | 4.39M | 4.68M |
| Gross Profit | 7.35M | 9.11M | 15.57M | 7.66M | 8.53M |
| SG&A Expenses | 16.01M | 12.13M | 11.36M | 10.69M | 9.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.45M | 21.83M | 20.04M | 21.01M | 17.12M |
| Operating Income | -13.58M | -8.29M | 55.00K | -8.96M | -3.91M |
| Income Before Tax | -17.07M | -11.51M | -2.75M | -12.83M | -8.01M |
| Income Tax Expenses | -14.00K | -- | -- | -- | 101.00K |
| Earnings from Continuing Operations | -17.06M | -11.51M | -2.75M | -12.83M | -8.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.06M | -11.51M | -2.75M | -12.83M | -8.11M |
| EBIT | -13.58M | -8.29M | 55.00K | -8.96M | -3.91M |
| EBITDA | -13.41M | -8.13M | 260.00K | -8.75M | -3.42M |
| EPS Basic | -0.19 | -0.13 | -0.03 | -0.17 | -0.12 |
| Normalized Basic EPS | -0.11 | -0.08 | -0.03 | -0.11 | -0.06 |
| EPS Diluted | -0.19 | -0.13 | -0.03 | -0.17 | -0.12 |
| Normalized Diluted EPS | -0.11 | -0.08 | -0.03 | -0.11 | -0.06 |
| Average Basic Shares Outstanding | 91.20M | 91.08M | 90.91M | 73.61M | 67.20M |
| Average Diluted Shares Outstanding | 91.20M | 91.08M | 90.91M | 73.61M | 67.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |